Last Update 30 Apr 26

Fair value Decreased 0.30%

ELV: Regulatory And Margin Risks Will Pressure 2026 Earnings Visibility

The updated analyst price target for Elevance Health edges to $331 from $332, as analysts factor in slightly stronger revenue growth and profit margin assumptions, along with a modestly lower future P/E multiple, following a mix of recent upgrades, raised targets, and a few cautious revisions across the Street.

Analyst Commentary

Street research on Elevance Health has been mixed, with several firms lifting price targets while others trim expectations or shift to a more cautious stance. Recent upgrades and higher targets highlight confidence in the company’s ability to manage margin and regulatory issues, but there is also a clear minority pointing to risks that could affect execution and valuation.

On the constructive side, some large banks have increased their price targets, citing factors such as Medicaid margin trends, the handling of Centers for Medicare and Medicaid Services related matters, and reiterated long term guidance. These views generally reflect confidence that existing headwinds are understood and already reflected in forecasts.

At the same time, a separate group of bearish analysts has reduced targets or downgraded the stock, arguing that the risk and reward balance is less attractive at current levels. These moves, alongside more neutral initiations, help explain why the Street’s aggregate target has only inched lower despite several high profile upward revisions.

Bearish Takeaways

Multiple bearish analysts have lowered price targets on Elevance Health, including one move to US$350 from US$413. This signals concern that prior expectations for the stock and earnings trajectory may have been too optimistic.
The recent downgrade at RBC Capital and target cuts from firms like Bernstein point to worries about the company’s ability to deliver against existing growth plans without pressure on returns or capital allocation.
Research highlighting margin pressure despite commentary around a positive regulatory backdrop suggests some analysts see limited room for upside if medical cost trends or regulatory outcomes do not evolve as expected.
The presence of both target reductions and a neutral initiation indicates that a portion of the Street is hesitant to assign a higher P/E multiple until there is clearer evidence on execution and the impact of sanctions and guidance on future results.

For you as an investor, the split in opinion means it is important to look closely at the assumptions behind both the bullish and bearish calls, including how much risk is being factored into earnings, margins, and the P/E multiple that analysts apply to Elevance Health.

What's in the News

House Judiciary Committee Republicans issued subpoenas to Elevance and seven other ACA insurers as part of an investigation into potential fraud tied to premium subsidies in the individual market, adding regulatory and legal focus on how plans handle these subsidies (Axios).
Elevance provided full year 2026 earnings guidance, indicating diluted EPS is expected to be at least $19.85, which includes the company’s estimate of the financial impact from the CMS matter.
From January 1, 2026 to March 31, 2026, Elevance repurchased 3,700,000 shares, or 1.68% of its shares, for $1.1 billion, and has completed repurchases of 525,920,743 shares for $53.78924 billion under the buyback that was announced on October 26, 2004.
Myomo announced its first network participation agreement with Elevance, covering Anthem affiliated Commercial, Medicare Advantage, and Medicaid plans, with contracts expected to become effective market by market through the second quarter of 2026 and ultimately reach 45,000,000 medical members.
Elevance and the National Diaper Bank Network launched a 12 month national pilot to provide free diapers to up to 75 families per month at 10 Medicaid Welcome Rooms, potentially reaching as many as 9,000 families in 2026 and producing research on links between diaper access and maternal and child health outcomes.

Valuation Changes

Fair Value: The fair value estimate has edged down slightly to $331.0 from $332.0.
Discount Rate: The discount rate assumption is effectively unchanged at 6.978%.
Revenue Growth: The long term revenue growth input has risen slightly to 69.96% from 68.96%.
Profit Margin: The profit margin assumption has moved higher to 3.15% from 3.04%.
Future P/E: The future P/E multiple applied in the model has been reduced to 12.07x from 13.49x.

1 view

Key Takeaways

Elevated costs in government-backed plans and greater reliance on value-based care could compress margins despite operational improvements and diversification strategies.
Increasing regulatory changes, political uncertainty, and provider sophistication in technology may erode pricing power and add to earnings volatility.
Margin and earnings growth are threatened by rising healthcare costs, regulatory uncertainty, slow Medicaid rate realignment, provider power, and integration risks from recent acquisitions.

Catalysts

About Elevance Health

Operates as a health benefits company in the United States.What are the underlying business or industry changes driving this perspective?

While Elevance Health benefits from the long-term aging population in the U.S. which is expected to drive ongoing demand and increase premium revenues, the company faces persistent pressures from accelerated cost trends in its ACA and Medicaid businesses. This dynamic is likely to weigh on near-term revenues and net margins, given lagging rate recovery from state partners and ongoing risk pool deterioration.
Despite significant advancements in technology and digital health integration-such as AI-enabled tools and analytics designed to drive administrative efficiencies and cost reductions-Elevance Health must contend with increasing sophistication among providers in using these same technologies for more aggressive coding and dispute resolution. This may continue to challenge cost controls and erode operating margins.
Although value-based care models are expanding within Elevance's portfolio (now comprising over one-third of benefit expense in downside risk arrangements), elevated utilization in high-cost categories like emergency room visits, behavioral health, and specialty pharmacy threaten to outweigh the benefits of these models, resulting in higher-than-anticipated benefit expense ratios and margin compression in the long term.
While strategic diversification through Carelon subsidiaries and risk-based services is expected to boost long-term service revenue and margin resilience, ongoing industry reforms-such as potential expiration of enhanced ACA subsidies and new Medicaid work requirements-introduce uncertainty about future enrollment levels and risk pool composition, putting pressure on both future revenue growth and margin visibility.
Even though the company is exercising disciplined pricing and investment in operational improvements, heavy exposure to government-backed business exposes Elevance Health to reimbursement risk, political uncertainty, and delays in rate alignment. These factors create potential for ongoing volatility in earnings, especially if policy shifts or future reforms suppress the share or profitability of private insurance.

Elevance Health Earnings and Revenue Growth

Elevance Health Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on Elevance Health compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming Elevance Health's revenue will remain fairly flat over the next 3 years.
The bearish analysts assume that profit margins will increase from 2.6% today to 3.1% in 3 years time.
The bearish analysts expect earnings to reach $6.4 billion (and earnings per share of $31.8) by about April 2029, up from $5.2 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $7.2 billion.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 12.1x on those 2029 earnings, down from 15.6x today. This future PE is lower than the current PE for the US Healthcare industry at 24.3x.
The bearish analysts expect the number of shares outstanding to decline by 3.88% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent elevated medical cost trends in the ACA and Medicaid businesses, driven by higher acuity, risk pool deterioration, and increased utilization-especially in behavioral health and specialty pharmacy-could erode net margins and constrain earnings recovery for several years.
Delays in Medicaid rate alignment due to lagging state responses and complex redetermination cycles create prolonged margin suppression, introducing significant uncertainty to the pace of margin improvement and potentially reducing revenue and profitability.
Regulatory and policy uncertainties, such as the expiration of ACA enhanced subsidies, new Medicaid work requirements, and more frequent eligibility reviews, may further destabilize enrollment and risk pools, intensifying margin volatility and threatening top-line growth.
Heightened provider bargaining power, aggressive coding practices-enabled by AI-and the misuse of dispute resolution processes are raising allowed amounts and compliance costs, which could compress operating margins and increase administrative expenses.
Scale-up and integration risk from recent acquisitions, combined with a strategic emphasis on embedding value-based care arrangements with greater downside risk, may subject Elevance Health to execution missteps and financial volatility, impacting both net income and long-term earnings visibility.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for Elevance Health is $331.0, which represents up to two standard deviations below the consensus price target of $388.95. This valuation is based on what can be assumed as the expectations of Elevance Health's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $474.0, and the most bearish reporting a price target of just $331.0.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $204.7 billion, earnings will come to $6.4 billion, and it would be trading on a PE ratio of 12.1x, assuming you use a discount rate of 7.0%.
Given the current share price of $376.63, the analyst price target of $331.0 is 13.8% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Elevance Health?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

ACA And Medicaid Will Squeeze Margins Though Tech Will Aid